The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...

Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, ...

Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into ...

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-? (FR?) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelin ...

Navigating the stock market requires a keen understanding of current economic indicators, sectoral shifts, and emerging ...

Research and development expenses were $41.5 million for the full year ended December 31, 2024, as compared to $47.9 million for the full year ended December 31, 2023. Higher net costs on the LNCB74 ...

(NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update on its subsidiary, Adimune, Inc., (“Adimune”) ...

FY’24 results showcase growth potential with 12% IRR, strategic acquisitions, and undervalued stock. Read more on TMO stock ...

Two of the Dow Jones Industrial Average's 30 components make for no-brainer buys, while another brand-name member continues ...

In today’s fast-evolving global economy, Asia has become a reliable destination for high-tech manufacturing and ...

Governor Charles Soludo of Anambra State condemned native doctors for misleading youths with promises of supernatural ...

Trelleborg Medical is staking its claim to the biopharmaceutical and medical componentry space, boasting its time-to-market ...